|
1
|
Vasuri F, Visani M, Acquaviva G, Brand T,
Fiorentino M, Pession A, Tallini G, D'Errico A and de Biase D: Role
of microRNAs in the main molecular pathways of hepatocellular
carcinoma. World J Gastroenterol. 24:2647–2660. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Giovannini C, Fornari F, Dallo R,
Gagliardi M, Nipoti E, Vasuri F, Coadă CA, Ravaioli M, Bolondi L
and Gramantieri L: MiR-199-3p replacement affects E-cadherin
expression through Notch1 targeting in hepatocellular carcinoma.
Acta Histochem. 120:95–102. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guan J, Liu Z, Xiao M, Hao F, Wang C, Chen
Y, Lu Y and Liang J: MicroRNA-199a-3p inhibits tumorigenesis of
hepatocellular carcinoma cells by targeting ZHX1/PUMA signal. Am J
Transl Res. 9:2457–2465. 2017.PubMed/NCBI
|
|
5
|
Ghosh A, Dasgupta D, Ghosh A, Roychoudhury
S, Kumar D, Gorain M, Butti R, Datta S, Agarwal S, Gupta S, et al:
MiRNA199a-3p suppresses tumor growth, migration, invasion and
angiogenesis in hepatocellular carcinoma by targeting VEGFA,
VEGFR1, VEGFR2, HGF and MMP2. Cell Death Dis. 8:e27062017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ren K, Li T, Zhang W, Ren J, Li Z and Wu
G: miR-199a-3p inhibits cell proliferation and induces apoptosis by
targeting YAP1, suppressing Jagged1-Notch signaling in human
hepatocellular carcinoma. J Biomed Sci. 23:792016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim JH, Badawi M, Park JK, Jiang J, Mo X,
Roberts LR and Schmittgen TD: Anti-invasion and anti-migration
effects of miR-199a-3p in hepatocellular carcinoma are due in part
to targeting CD151. Int J Oncol. 49:2037–2045. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Henry JC, Park JK, Jiang J, Kim JH,
Nagorney DM, Roberts LR, Banerjee S and Schmittgen TD: miR-199a-3p
targets CD44 and reduces proliferation of CD44 positive
hepatocellular carcinoma cell lines. Biochem Biophys Res Commun.
403:120–125. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fornari F, Milazzo M, Chieco P, Negrini M,
Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L and Gramantieri
L: MiR-199a-3p regulates mTOR and c-Met to influence the
doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res.
70:5184–5193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Callegari E, D'Abundo L, Guerriero P,
Simioni C, Elamin BK, Russo M, Cani A, Bassi C, Zagatti B,
Giacomelli L, et al: miR-199a-3p modulates MTOR and PAK4 pathways
and inhibits tumor growth in a hepatocellular carcinoma transgenic
mouse model. Mol Ther Nucleic Acids. 11:485–493. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Varshney A, Panda JJ, Singh AK, Yadav N,
Bihari C, Biswas S, Sarin SK and Chauhan VS: Targeted delivery of
microRNA-199a-3p using self-assembled dipeptide nanoparticles
efficiently reduces hepatocellular carcinoma in mice. Hepatology.
67:1392–1407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo C, Yin D, Zhan H, Borjigin U, Li C,
Zhou Z, Hu Z, Wang P, Sun Q, Fan J, et al: microRNA-501-3p
suppresses metastasis and progression of hepatocellular carcinoma
through targeting LIN7A. Cell Death Dis. 9:5352018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu H, Chen W, Zhi X, Chen EJ, Wei T,
Zhang J, Shen J, Hu LQ, Zhao B, Feng XH, et al: Tumor-derived
exosomes promote tumor self-seeding in hepatocellular carcinoma by
transferring miRNA-25-5p to enhance cell motility. Oncogene.
37:4964–4978. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin XJ, Fang JH, Yang XJ, Zhang C, Yuan Y,
Zheng L and Zhuang SM: Hepatocellular carcinoma cell-secreted
exosomal MicroRNA-210 promotes angiogenesis in vitro and in vivo.
Mol Ther Nucleic Acids. 11:243–252. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fang JH, Zhang ZJ, Shang LR, Luo YW, Lin
YF, Yuan Y and Zhuang SM: Hepatoma cell-secreted exosomal
microRNA-103 increases vascular permeability and promotes
metastasis by targeting junction proteins. Hepatology.
68:1459–1475. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fang T, Lv H, Lv G, Li T, Wang C, Han Q,
Yu L, Su B, Guo L, Huang S, et al: Tumor-derived exosomal
miR-1247-3p induces cancer-associated fibroblast activation to
foster lung metastasis of liver cancer. Nat Commun. 9:1912018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yan YF, Gong FM, Wang BS and Zheng W:
MiR-425-5p promotes tumor progression via modulation of CYLD in
gastric cancer. Eur Rev Med Pharmacol Sci. 21:2130–2136.
2017.PubMed/NCBI
|
|
20
|
Zhang Z, Li Y, Fan L, Zhao Q, Tan B, Li Z
and Zang A: microRNA-425-5p is upregulated in human gastric cancer
and contributes to invasion and metastasis in vitro and in vivo.
Exp Ther Med. 9:1617–1622. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fang F, Song T, Zhang T, Cui Y, Zhang G
and Xiong Q: MiR-425-5p promotes invasion and metastasis of
hepatocellular carcinoma cells through SCAI-mediated dysregulation
of multiple signaling pathways. Oncotarget. 8:31745–31757.
2017.PubMed/NCBI
|
|
22
|
Sun L, Jiang R, Li J, Wang B, Ma C, Lv Y
and Mu N: MicoRNA-425-5p is a potential prognostic biomarker for
cervical cancer. Ann Clin Biochem. 54:127–133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu L, Zhao Z, Zhou W, Fan X, Zhan Q and
Song Y: Enhanced expression of miR-425 promotes esophageal squamous
cell carcinoma tumorigenesis by targeting SMAD2. J Genet Genomics.
42:601–611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu W, Ma Y, Zhuang X and Jin X:
MicroRNA-425 is downregulated in nasopharyngeal carcinoma and
regulates tumor cell viability and invasion by targeting
hepatoma-derived growth factor. Oncol Lett. 15:6345–6351.
2018.PubMed/NCBI
|
|
25
|
Quan J, Li Y, Pan X, Lai Y, He T, Lin C,
Zhou L, Zhao L, Sun S, Ding Y, et al: Oncogenic miR-425-5p is
associated with cellular migration, proliferation and apoptosis in
renal cell carcinoma. Oncol Lett. 16:2175–2184. 2018.PubMed/NCBI
|
|
26
|
Liu P, Hu Y, Ma L, Du M, Xia L and Hu Z:
miR-425 inhibits melanoma metastasis through repression of PI3K-Akt
pathway by targeting IGF-1. Biomed Pharmacother. 75:51–57. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Weigel D and Jäckle H: The fork head
domain: A novel DNA binding motif of eukaryotic transcription
factors? Cell. 63:455–456. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yong JS, Intriago-Baldeón DP and Lam EW:
FOXD3 controls pluripotency through modulating enhancer activity.
Stem Cell Investig. 3:172016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu LL, Lu SX, Li M, Li LZ, Fu J, Hu W,
Yang YZ, Luo RZ, Zhang CZ and Yun JP: FoxD3-regulated microRNA-137
suppresses tumour growth and metastasis in human hepatocellular
carcinoma by targeting AKT2. Oncotarget. 5:5113–5124. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He G, Hu S, Zhang D, Wu P, Zhu X, Xin S,
Lu G, Ding Y and Liang L: Hypermethylation of FOXD3 suppresses cell
proliferation, invasion and metastasis in hepatocellular carcinoma.
Exp Mol Pathol. 99:374–382. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin H, Meng T, Zhou L, Zhao F, Li X, Li Y,
Hu M, Chen H and Song D: FOXD3 regulates anaplastic thyroid cancer
progression. Oncotarget. 8:33644–33651. 2017.PubMed/NCBI
|
|
32
|
He GY, Hu JL, Zhou L, Zhu XH, Xin SN,
Zhang D, Lu GF, Liao WT, Ding YQ and Liang L: The
FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis in
human colorectal cancer. Br J Cancer. 115:1367–1378. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li K, Guo Q, Yang J, Chen H, Hu K, Zhao J,
Zheng S, Pang X, Zhou S, Dang Y and Li L: FOXD3 is a tumor
suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK
signal pathway. Oncotarget. 8:5048–5056. 2017.PubMed/NCBI
|
|
34
|
Sarkar S, O'Connell MR, Okugawa Y, Lee BS,
Toiyama Y, Kusunoki M, Daboval RD, Goel A and Singh P: FOXD3
regulates CSC marker, DCLK1-S, and invasive potential: Prognostic
implications in colon cancer. Mol Cancer Res. 15:1678–1691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kubic JD, Little EC, Kaiser RS, Young KP
and Lang D: FOXD3 promotes PAX3 expression in melanoma cells. J
Cell Biochem. 117:533–541. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kubic JD, Lui JW, Little EC, Ludvik AE,
Konda S, Salgia R, Aplin AE and Lang D: PAX3 and FOXD3 Promote
CXCR4 Expression in Melanoma. J Biol Chem. 290:21901–21914. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Weiss MB, Abel EV, Dadpey N and Aplin AE:
FOXD3 modulates migration through direct transcriptional repression
of TWIST1 in melanoma. Mol Cancer Res. 12:1314–1323. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar :
|
|
39
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M
and Rajewsky N: Combinatorial microRNA target predictions. Nat
Genet. 37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li H, Yang T, Shang D and Sun Z: miR-1254
promotes lung cancer cell proliferation by targeting SFRP1. Biomed
Pharmacother. 92:913–918. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen H, Yang Y, Wang J, Shen D, Zhao J and
Yu Q: miR-130b-5p promotes proliferation, migration and invasion of
gastric cancer cells via targeting RASAL1. Oncol Lett.
15:6361–6367. 2018.PubMed/NCBI
|
